Research programme: vitamin D receptor agonists - Eli LillyAlternative Names: LY-2108491; LY-2109866; VDRM II
Latest Information Update: 16 Jul 2016
At a glance
- Originator Eli Lilly
- Mechanism of Action Calcitriol receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Neuromuscular disorders; Osteoporosis; Psoriasis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Neuromuscular-disorders in USA (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Osteoporosis in USA (PO)
- 15 Sep 2009 Preclinical trials in Osteoporosis in USA (PO)